<DOC>
	<DOC>NCT00504881</DOC>
	<brief_summary>This study will compare the safety and efficacy of Brivaracetam at flexible dose with Placebo in subjects suffering from Epilepsy.</brief_summary>
	<brief_title>Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Subjects were aged from 16 to 70 years, inclusive. Subjects under 18 years of age were only included where legally permitted and ethically accepted Subjects had wellcharacterized localizationrelated Epilepsy or generalized Epilepsy according to the International League Against Epilepsy (ILAE) classification For subjects suffering from localizationrelated Epilepsy: subjects had at least 2 PartialOnset Seizures (POSs) whether or not secondarily generalized per month during the 3 months preceding Visit 1 according to the ILAE classification For subjects suffering from localizationrelated Epilepsy: subjects had at least 4 PartialOnset Seizures (POSs) whether or not secondarily generalized during the 4week Baseline Period according to the ILAE classification For subjects suffering from generalized Epilepsy: subjects had at least 2 Type IIseizure days per month during the 3 months preceding Visit 1 according to the ILAE classification For subjects suffering from generalized Epilepsy: subjects had at least 4 Type IIseizure days during the 4 week Baseline Period according to the ILAE classification Subjects were uncontrolled while treated by 1 to 3 permitted concomitant Antiepileptic Drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant AED For subjects who suffered from localizationrelated Epilepsy: history or presence of Seizures occurring only in clusters (too frequently or indistinctly separated to be reliably counted) before Visit 2 or occurring only as Type IA nonmotor Subjects with a history or presence of Status Epilepticus during the year preceding Visit 1 or during Baseline</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Brivaracetam</keyword>
	<keyword>Partial Onset Seizures</keyword>
</DOC>